Oncology trials are complex. New technologies creating cutting-edge immunotherapy treatments are promising but add more complexity to your study. The Medelis clinical research management team is accustomed to handling most targets in oncology, including cutting-edge immunotherapy treatments and precision oncology medicine.
Medelis’ team includes world-class oncology drug development thought leaders who understand the future of personalized medicine and threshold of credibility trials. Our extensive worldwide contacts and involvement with the research community keep us close to research trends and developments.
With Medelis, you don’t get inexperienced CRAs and PM and the bait and switch tactics of some of the big CROs. We are not a training ground for people just starting in clinical research, or even oncology. All of our operational resources are highly experienced and have proven experience in oncology studies. You get a trusted team, by your side, proactively managing your study.
In our previous article, we outlined how AI may improve different areas of the oncology drug development process. The integration… [read more]
Read articleThe release of GPT 3.5 and the improvement of large language models (LLMs) has captured the imagination of many around… [read more]
Read articleThe U.S. Food and Drug Administration (FDA) recently issued new guidance on the diversity of clinical trials, encouraging sponsors to… [read more]
Read articleOncology studies can be complex. For immuno-oncology studies, there are an entirely different set of complexities that cause additional delays. Immuno-oncology is a promising area of research, with thousands of new studies launching each year. Medelis has been pioneering immunotherapy studies since 2008, running many CAR T-cell therapy studies, checkpoint inhibitor studies and bispecific antibody treatment studies.